ArticleThe Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology2025
Elevated Serum Soluble Tim-3 in Primary Biliary Cholangitis: Lack of Correlation with Cytokines, Chemokines, and Clinical Parameters.
Article in The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsSoluble Tim-3 (sTim-3) has been implicated in primary biliary cholangitis (PBC), an autoimmune liver disease, though its clinical significance remains unclear. This study aimed to evaluate the associations between sTim-3, Galectin-9, and cytokines in PBC, as well as their potential prognostic utility. MATERIALS AND
methodsA total of 55 PBC patients were enrolled (45 without overlapping conditions) and serum levels of sTim-3, Galectin-9, and 18 cytokines/chemokines were measured. Disease severity was assessed using the model for end-stage liver disease (MELD), MELD-Na, and Mayo risk score (MRS) 1994, alongside fibrosis-4 (FIB-4) index and monocyte-lymphocyte ratio (MLR). Patients were stratified by fibrosis stage, cirrhosis status, Child-Pugh score, and treatment duration, with intergroup parameter comparisons performed. The least absolute shrinkage and selection operator regression identified potential risk factors for MRS1994, followed by multivariate linear regression analysis.
resultsCompared to healthy controls, PBC patients exhibited elevated sTim-3 and reduced Galectin-9, though neither biomarker cor related with clinical parameters. Advanced disease stages were associated with increased MLR, interferon-gamma (IFN-γ), interleukin (IL)-6, IL-8, C-C motif chemokine ligand 3 (CCL3), CCL20, and C-X3-C motif chemokine ligand 1 (CX3CL1). The MELD/MELD-Na scores strongly correlated with IL-6, TNF-α, IFN-γ, CCL3, and CCL20, while IL-6 and CX3CL1 linked to FIB-4 index. Multivariate analysis identi fied MLR, albumin/globulin (A/G) ratio, TNF-α, IL-6, and CX3CL1 as independent predictors of MRS1994.
conclusionAlthough sTim-3 and Galectin-9 dysregulation lacked direct clinical relevance, MLR, A/G ratio, cirrhosis status, and inflam matory markers (TNF-α, IL-6, CX3CL1) emerged as robust predictors of disease severity (MELD) and prognosis (MRS1994), highlighting their potential for non-invasive risk stratification in PBC. Cite this article as: Xu J, Ma H, Dang F, et al. Elevated serum soluble tim-3 in primary biliary cholangitis: lack of correlation with cytokines, chemokines, and clinical parameters. Turk J Gastroenterol. 2026;37(2):196-207.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.